Approximately 5% of breast cancer patients harbor KRAS mutations in the MAPK pathway, leading to continuous activation of PI3K [15], and the frequency of KRAS mutation is 1.56% in the COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). The gene discussed is KRAS; the disease is breast cancer.